NAPLEX • Pharmacy Management And Leadership

Risk Management And Error Prevention

Systematic strategies pharmacists use to identify, mitigate, and prevent medication errors that threaten patient safety.

NAPLEX emblem with a medicine bottle, dosage calculator, and verification checks.
Inside this lesson 10 sections 5 questions 7 figures

SECTION 1

Historical Context & Motivation

The modern framework for risk management in pharmacy practice did not arise in a vacuum; it was forged by decades of tragic medication errors, landmark regulatory actions, and evolving patient safety science. Before the mid-twentieth century, medication errors were largely treated as isolated failures of individual competence rather than symptoms of systemic design flaws. Pharmacists and physicians operated within a blame-centered culture in which the person who made the error bore sole responsibility, while the organizational conditions that enabled the error remained unexamined. Understanding this history is essential because it reveals how pharmacy transitioned from punitive accountability to the proactive, systems-oriented safety culture that now defines best practice.

1999 • To Err Is Human

The Institute of Medicine (IOM) published To Err Is Human: Building a Safer Health System, estimating that 44,000–98,000 Americans died annually from preventable medical errors, galvanizing a national patient safety movement.

2003 • Joint Commission & National Patient Safety Goals

The Joint Commission established its first set of National Patient Safety Goals (NPSGs), requiring healthcare organizations—including pharmacies—to implement standardized error-prevention practices such as medication reconciliation and 'do not use' abbreviation lists.

2005 • Patient Safety and Quality Improvement Act

Congress enacted this federal law creating Patient Safety Organizations (PSOs) and protecting voluntarily reported safety data from legal discovery, encouraging a culture of open error reporting without fear of litigation.

2007 • ISMP High-Alert Medication List

The Institute for Safe Medication Practices (ISMP) formalized and widely disseminated its list of high-alert medications—drugs that bear a heightened risk of significant patient harm when used in error—serving as a cornerstone for pharmacy risk stratification.

2020s • Technology-Driven Safety Systems

Widespread adoption of barcode medication administration (BCMA), computerized provider order entry (CPOE), clinical decision support systems (CDSS), and smart infusion pumps has made technology a central pillar of modern pharmacy error prevention.

This historical trajectory raises a critical question that still animates pharmacy practice today: How can pharmacists design systems, workflows, and cultures that anticipate human fallibility and intercept errors before they reach the patient? The answer lies in the structured discipline of risk management and error prevention, which integrates human factors engineering, just culture philosophy, regulatory compliance, and technology into a coherent safety framework.

SECTION 2

Core Principles & Definitions

Effective risk management in pharmacy rests on several interrelated principles that, taken together, create a resilient safety net around the medication-use process. A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare professional, patient, or consumer, as defined by the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP). Risk management is the systematic identification, assessment, and prioritization of risks followed by coordinated application of resources to minimize, monitor, and control the probability or impact of those adverse events. Understanding these foundational definitions allows the pharmacist to differentiate between adverse drug events (ADEs), which include any injury resulting from medication use regardless of preventability, and adverse drug reactions (ADRs), which are noxious and unintended responses occurring at normal doses used for prophylaxis, diagnosis, or therapy.

1

Swiss Cheese Model

James Reason's model posits that hazards penetrate multiple layers of defense—each with its own 'holes.' An error reaches the patient only when the holes in every successive barrier momentarily align, emphasizing that system redundancy is the primary safeguard.
2

Just Culture

A balanced accountability framework distinguishing human error (inadvertent, consoled), at-risk behavior (coached), and reckless behavior (disciplined). This replaces blanket blame with proportional responses.
3

High-Reliability Organization (HRO)

Pharmacies aspire to HRO principles: preoccupation with failure, reluctance to simplify, sensitivity to operations, commitment to resilience, and deference to expertise. These traits encourage proactive hazard identification rather than reactive damage control.
4

Root Cause Analysis (RCA)

A retrospective, structured method for investigating sentinel events to uncover underlying system, process, and human factors that contributed to an error. RCA identifies latent conditions rather than stopping at the proximate cause.
5

Failure Mode and Effects Analysis (FMEA)

A prospective risk assessment tool that systematically evaluates each step in a process for potential failure modes, their effects, and their causes. Each mode receives a Risk Priority Number (RPN) guiding corrective action prioritization.
✦

KEY TAKEAWAY

Think of pharmacy error prevention like an airport security system. No single checkpoint—the ticket counter, the TSA screening, the gate agent—catches every threat alone. Safety emerges because each layer compensates for the weaknesses of the others. When a medication error reaches a patient, it means every defensive layer had a gap at the same moment, much like the Swiss Cheese Model describes. The pharmacist's role is to add layers, shrink holes, and ensure the system as a whole is robust even when individual humans inevitably err.

SECTION 3

Visual Explanation — The Swiss Cheese Model in Pharmacy

Swiss Cheese Model — Pharmacy Medication-Use ProcessHAZARDPrescribingTranscribingDispensingAdministeringMonitoringError trajectoryEach slice is a defensive barrier. Holes = latent weaknesses. Error reaches the patient only when all holes align.
The diagram illustrates five sequential barriers in the medication-use process: prescribing, transcribing, dispensing, administering, and monitoring. The elliptical openings represent latent weaknesses—staff fatigue, look-alike drug names, inadequate labeling—that may allow a hazard to pass through. The red dashed line shows how an error trajectory can penetrate successive layers when holes momentarily align.

The Swiss Cheese Model, originally proposed by James Reason in 1990, provides the conceptual backbone for pharmacy safety systems. In the context of the medication-use process, each "slice" represents an organizational barrier: physician order verification, pharmacist clinical review, barcode scanning at dispensing, nurse double-check at administration, and post-administration outcome monitoring. The model teaches that safety is not achieved by perfecting any single slice—because all slices will always have holes—but by ensuring that the holes in adjacent slices rarely align. This insight drives strategies like independent double-checks for high-alert medications, tall-man lettering to differentiate look-alike drug names, and forced functions embedded in technology that physically prevent an incorrect action from proceeding.

SECTION 4

How It Works — Types of Medication Errors & Error Taxonomy

To manage risk effectively, pharmacists must first understand the taxonomy of medication errors. The NCC MERP Error Category Index classifies errors along a severity continuum from Category A (circumstances with capacity to cause error, but no actual error occurred) to Category I (error that contributed to or resulted in patient death). This classification system enables organizations to prioritize interventions by focusing on the most harmful error types. Additionally, errors can be categorized by the stage in the medication-use process at which they occur—prescribing, transcribing/order entry, dispensing, administering, or monitoring—or by their cognitive mechanism, such as knowledge-based mistakes, rule-based mistakes, slips (execution failures in an automatic task), and lapses (memory failures).

NCC MERP Error Severity Categories

CategoryDescriptionOutcome Level
ACircumstances or events that have the capacity to cause errorNo error
BAn error occurred but the error did not reach the patientNo harm
CAn error reached the patient but did not cause harmNo harm
DAn error reached the patient and required monitoring or intervention to confirm no harmNo harm
EAn error occurred that contributed to or resulted in temporary harm requiring interventionHarm
FAn error contributed to or resulted in temporary harm requiring initial or prolonged hospitalizationHarm
GAn error contributed to or resulted in permanent patient harmHarm
HAn error occurred that required intervention necessary to sustain lifeHarm
IAn error contributed to or resulted in patient deathDeath

NCC MERP Index for Categorizing Medication Errors

Failure Mode and Effects Analysis (FMEA) — Risk Priority Number

While the NCC MERP index is retrospective, FMEA provides a prospective, quantitative framework. For each potential failure mode in a pharmacy process, a multidisciplinary team assigns scores for three dimensions on a 1–10 scale: Severity (S) of harm if the failure occurs, Occurrence (O) or frequency of the failure, and Detectability (D) or how easily the failure is identified before it causes harm. These three scores are multiplied to yield the Risk Priority Number (RPN), which ranges from 1 to 1,000.

RISK PRIORITY NUMBER

RPN=S×O×DRPN = S × O × D

Where S = Severity (1–10), O = Occurrence likelihood (1–10), D = Detection difficulty (1 = easily detected, 10 = virtually undetectable). Higher RPN values indicate higher-priority risks requiring immediate intervention.

MEDICATION ERROR RATE

ErrorRate=(NumberofErrors÷TotalOpportunitiesforError)×100Error Rate = (Number of Errors ÷ Total Opportunities for Error) × 100%

This basic metric quantifies organizational performance. 'Opportunities for error' may be defined as total prescriptions dispensed, total doses administered, or total order-entry actions depending on the process step under evaluation.

SECTION 5

Detailed Breakdown — Error Prevention Strategies

Error prevention strategies in pharmacy can be organized hierarchically according to their effectiveness, from the most reliable (those that eliminate the hazard entirely) to the least reliable (those that depend on human vigilance alone). This hierarchy parallels the industrial safety concept of the hierarchy of controls, which has been adapted for healthcare settings. Understanding where each strategy falls on this spectrum enables pharmacy managers to allocate resources toward high-leverage interventions rather than relying solely on education, policies, or reminders—strategies that are necessary but insufficient in isolation.

Hierarchy of Pharmacy Error Prevention StrategiesEFFECTIVENESSHIGHLOWForcing Functionse.g., remove concentrated KCl from floor stockAutomation & ComputerizationCPOE, BCMA, smart pumps, CDSS alertsStandardization & ProtocolsDose-range checking, order sets, formulary limitsIndependent Double-ChecksSecond pharmacist verification, nurse co-signEducation & AwarenessTraining, newsletters, warning labels
The inverted pyramid shows error prevention strategies ranked from most effective (top) to least effective (bottom). Forcing functions physically eliminate the possibility of error—for example, removing concentrated potassium chloride from nursing unit stock completely prevents accidental IV push administration. At the base, education and awareness campaigns are the least reliable because they depend entirely on sustained human vigilance and memory.

Key Technology-Based Strategies

  • ✓ Computerized Provider Order Entry (CPOE): Eliminates transcription errors by requiring prescribers to enter orders electronically, triggering real-time clinical decision support alerts for allergies, drug–drug interactions, and dose-range violations.
  • ✓ Barcode Medication Administration (BCMA): Requires scanning of both patient wristband and medication barcode before administration, verifying the five rights (right patient, drug, dose, route, time) at the point of care.
  • ✓ Smart Infusion Pumps: Feature drug libraries with pre-programmed dose limits; the pump issues soft or hard stops when a nurse programs a rate or concentration outside the approved range, preventing catastrophic IV medication errors.
  • ✓ Tall-Man Lettering: Uses uppercase letters to emphasize the distinct portions of look-alike/sound-alike drug name pairs (e.g., hydrOXYzine vs. hydrALAZINE), reducing confusion during selection.
  • ✓ Automated Dispensing Cabinets (ADCs): Restrict medication access through biometric authentication and guided drawer systems, limiting opportunities for wrong-drug selection at the nursing unit.

SECTION 6

Worked Example — Conducting an FMEA for an IV Compounding Process

Consider a hospital pharmacy tasked with prospectively assessing the risks in its IV admixture compounding workflow. The pharmacy director assembles a multidisciplinary team including a pharmacist, a pharmacy technician, a nurse, and a quality assurance specialist. They select the process step of selecting the correct base solution from the IV room shelf as a focus for FMEA. They identify a failure mode: the technician selects dextrose 5% in water (D5W) instead of normal saline (NS) 0.9% because the bags are stored adjacent to one another and have similar packaging.

FMEA for IV Base Solution Selection Error

  1. 1

    Step 1 — Define the Failure Mode

    The failure mode is: 'Pharmacy technician selects D5W bag instead of NS 0.9% bag for IV compounding.' The effect of this failure is that the patient receives the wrong base solution, potentially causing electrolyte imbalances or hyperglycemia. The cause is identified as similar packaging appearance and adjacent storage on the same shelf.
  2. 2

    Step 2 — Assign Severity (S)

    The team evaluates the potential harm. For a patient with diabetes or critical fluid requirements, receiving the wrong base solution could lead to significant hyperglycemia or inadequate sodium replacement. The team assigns a Severity score of 7 (high harm potential for vulnerable patients, though not immediately life-threatening for most).
    S = 7
  3. 3

    Step 3 — Assign Occurrence (O)

    Review of incident reports over the past 12 months reveals that base solution mix-ups in IV compounding occur approximately twice per quarter. Given the volume of IV orders (roughly 200 per week), this frequency is moderate. The team assigns an Occurrence score of 5.
    O = 5
  4. 4

    Step 4 — Assign Detectability (D)

    Currently, the pharmacist performs a final visual check of the compounded product, but the bags of D5W and NS look very similar once additives are mixed in. There is no barcode verification at the compounding step. The team assigns a Detectability score of 6 (moderately difficult to detect before it reaches the patient).
    D = 6
  5. 5

    Step 5 — Calculate RPN and Prioritize

    Applying the formula: RPN = S × O × D = 7 × 5 × 6 = 210. The team's threshold for mandatory corrective action is an RPN ≥ 125. Because 210 exceeds this threshold, the team recommends three interventions: (1) separate D5W and NS on different shelves with color-coded shelf labels, (2) implement barcode scanning at the compounding step to verify base solution selection, and (3) apply auxiliary warning stickers on D5W bags highlighting the dextrose content. After implementation, they project revised scores of S = 7 (unchanged—severity doesn't change), O = 2, and D = 2, yielding a new RPN = 7 × 2 × 2 = 28, well below the action threshold.
    Pre-intervention RPN = 210 → Post-intervention RPN = 28

SECTION 7

Strengths, Limitations, and Comparisons of Risk Tools

Pharmacists have access to both retrospective tools (Root Cause Analysis) and prospective tools (FMEA) for managing risk. Each has distinct strengths and limitations, and choosing the appropriate tool depends on whether the organization is responding to an event that has already occurred or proactively evaluating a process before harm results. Additionally, error reporting systems—both internal incident reporting and external programs such as the FDA MedWatch program and ISMP Medication Errors Reporting Program (MERP)—serve as data sources that feed into both RCA and FMEA processes.

FeatureRoot Cause Analysis (RCA)FMEA
TimingRetrospective (after an event)Prospective (before an event)
TriggerSentinel event or serious near-missNew process, process redesign, or proactive safety initiative
OutputIdentification of contributing factors; corrective action planRisk Priority Numbers (RPNs) for each failure mode; ranked action priorities
StrengthDeep investigation into a specific event; identifies latent system failuresSystematic evaluation of entire process; prevents harm before it occurs
LimitationReactive; hindsight bias may influence analysis; resource-intensiveScoring can be subjective; requires multidisciplinary team commitment; time-consuming
Required byJoint Commission (for sentinel events)Joint Commission (at least one per year for high-risk processes)

Comparison of RCA and FMEA as pharmacy risk management tools

✦

KEY TAKEAWAY

Think of RCA and FMEA as the difference between a post-crash accident investigation and a pre-flight checklist. The accident investigation (RCA) dissects what went wrong to prevent recurrence; the pre-flight checklist (FMEA) anticipates everything that could go wrong before the plane ever leaves the ground. The strongest safety cultures use both: reactive learning from events that slip through, and proactive design that prevents most events from occurring in the first place.

SECTION 8

Connection to Advanced Safety Science & Regulatory Frameworks

The principles of risk management and error prevention discussed in this lesson serve as the foundation for increasingly sophisticated safety science concepts that pharmacy students will encounter in advanced practice and leadership roles. Safety-II is an emerging paradigm that complements the traditional Safety-I approach. While Safety-I focuses on what goes wrong (errors, incidents, near-misses), Safety-II examines what goes right—how healthcare professionals successfully adapt to variable conditions every day—and seeks to amplify those adaptive capacities. In the Safety-II view, humans are not primarily the source of error but rather the source of resilience. This concept is closely tied to Resilience Engineering, which studies how complex systems maintain acceptable performance under varying and often unexpected conditions.

DimensionFoundational (This Lesson)Advanced (Safety-II / Resilience Engineering)
FocusWhat went wrong; preventing recurrence of specific error typesWhat goes right; understanding and enhancing everyday adaptive performance
View of humansPotential source of error; need constraints and barriersPrimary source of flexibility and resilience; need support and resources
MethodologyRCA, FMEA, incident reporting, error classificationWork-as-done vs. work-as-imagined analysis, functional resonance analysis method (FRAM)
GoalReduce errors to as close to zero as achievableEnsure that as many outcomes as possible are acceptable under varying conditions

Foundational vs. advanced safety science paradigms

From a regulatory perspective, pharmacists must also be aware of USP <800> (Hazardous Drug Handling), USP <797> (Pharmaceutical Compounding—Sterile Preparations), and REMS (Risk Evaluation and Mitigation Strategies) programs mandated by the FDA for certain high-risk medications. REMS represent a drug-specific application of risk management, requiring elements such as medication guides, communication plans, Elements to Assure Safe Use (ETASU), and implementation systems. As pharmacy practice continues to evolve, the integration of artificial intelligence for predictive error analytics, pharmacogenomic-guided dosing, and real-time surveillance dashboards will further transform the landscape of risk management.

⚠

NAPLEX Exam Tip

The NAPLEX frequently tests knowledge of ISMP high-alert medication lists, look-alike/sound-alike drug pairs, the five rights of medication administration, NCC MERP error categories, and the distinction between RCA (retrospective) and FMEA (prospective). Be prepared to identify which error prevention strategy is most effective for a given scenario—remember that forcing functions and automation are always preferred over education-only interventions.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A hospital pharmacy discovers that a nurse administered metoprolol IV push to a patient who was prescribed metformin PO. Using the Swiss Cheese Model, explain how this error could have passed through multiple defensive barriers. Identify at least three 'holes' in different slices that may have aligned to allow this event.
Show answer
In the Swiss Cheese Model, this error passed through at least three defensive layers. First, at the prescribing/order entry layer, the physician may have selected metoprolol from a drop-down menu instead of metformin due to similar drug name beginnings (a look-alike/sound-alike problem), and the CPOE system did not generate an alert because metoprolol is not contraindicated for the patient. Second, at the pharmacist verification layer, the pharmacist may have been experiencing alert fatigue from excessive clinical decision support notifications and approved the order without thorough review, or the order arrived during a high-volume period. Third, at the administration layer, the nurse may not have performed an independent double-check or the BCMA system was bypassed due to a workaround. The alignment of these latent weaknesses—similar naming, alert fatigue, and technology workaround—allowed the error trajectory to penetrate all slices and reach the patient.

Question 2: BASIC CALCULATION

A community pharmacy dispensed 12,480 prescriptions last quarter. During that period, 37 dispensing errors were identified (caught before reaching patients) and 5 errors reached patients. Calculate: (a) the total error rate, and (b) the rate of errors reaching patients.
Show answer
Total errors = 37 + 5 = 42. (a) Total error rate = (42 ÷ 12,480) × 100% = 0.336%. (b) Rate of errors reaching patients = (5 ÷ 12,480) × 100% = 0.040%. These metrics reveal that while the overall error rate is approximately 0.34%, the vast majority of errors (37 out of 42, or 88.1%) were intercepted before reaching patients, indicating that the pharmacy's verification systems are functioning as important safety barriers. However, the 5 errors that reached patients represent opportunities for process improvement, and an investigation into these specific events should be conducted to identify common contributing factors.

Question 3: INTERMEDIATE

A pharmacy team conducts an FMEA on the automated dispensing cabinet (ADC) restocking process. They identify a failure mode: 'Technician loads vancomycin 1 g vial into the drawer designated for vecuronium.' The team assigns Severity = 10 (vecuronium is a neuromuscular blocker—wrong administration could be fatal), Occurrence = 3 (rare but has happened at other institutions), and Detectability = 8 (ADC uses matrix drawers without individual pocket assignments, so the error would be difficult to detect). Calculate the RPN and recommend at least two interventions, explaining how each would reduce a specific FMEA dimension.
Show answer
RPN = S × O × D = 10 × 3 × 8 = 240. This exceeds typical action thresholds (commonly 100–150) and demands immediate corrective action. Intervention 1: Replace matrix drawers with individual lidded pockets that use barcode-verified restocking—the technician must scan each vial and the pocket before the lid opens. This reduces Detectability from 8 to approximately 2, because the system physically prevents loading into the wrong pocket. Intervention 2: Store neuromuscular blockers in a separate, locked ADC section requiring a second verification step, reducing Occurrence from 3 to 1 by eliminating the physical proximity of these high-alert medications to other drugs. After both interventions, the revised RPN = 10 × 1 × 2 = 20, representing a 91.7% reduction in risk priority. Severity remains at 10 because the inherent danger of vecuronium cannot be mitigated by process changes—it can only be addressed by preventing the error from occurring.

Question 4: APPLIED

You are the pharmacy manager at a 200-bed community hospital. Over the past six months, your incident reporting system has captured 14 events involving insulin dosing errors—8 during prescribing, 4 during administration, and 2 during dispensing. Insulin is classified as a high-alert medication by ISMP. Design a multi-layered error prevention plan that addresses at least three stages of the medication-use process. For each intervention, identify where it falls on the hierarchy of error prevention effectiveness.
Show answer
Given that prescribing accounts for 57% of insulin errors, the first intervention targets order entry: implement standardized insulin order sets within the CPOE system that include weight-based dosing calculations, mandatory indication fields, and hard-stop alerts for doses exceeding facility-approved maximum ranges. This represents the Automation/Computerization level of the hierarchy. Second, at the dispensing stage, require barcode scanning verification of insulin products during both compounding and dispensing, ensuring that the concentration, type (regular vs. glargine vs. lispro), and dose match the verified order. This also falls under Automation. Third, at the administration stage, mandate independent double-checks by two licensed professionals before any insulin dose is administered—the second verifier must independently calculate the expected dose before viewing the first nurse's calculation. This falls under Independent Double-Checks on the hierarchy. Fourth, as a forcing function (highest effectiveness), remove insulin from any ADC matrix drawers and place all insulin products in individually lidded, barcode-locked pockets. Finally, implement a monthly insulin safety dashboard reviewed in pharmacy and therapeutics committee meetings, which functions at the Education/Awareness level but is essential for sustaining the other interventions and identifying emerging trends.

Question 5: CRITICAL THINKING

A hospital implements a comprehensive CDSS that generates drug interaction alerts. After six months, pharmacists report that they override 92% of alerts. The quality improvement team proposes reducing the number of alerts by raising the severity threshold for triggering notifications. Critically analyze this proposal using the concepts of alert fatigue, just culture, and the Swiss Cheese Model. What are the risks and benefits, and what alternative or complementary approaches might you recommend?
Show answer
This scenario presents a classic safety paradox: the defensive barrier (CDSS alerts) has become so burdensome that it is functionally compromised—a 92% override rate suggests that pharmacists have developed alert fatigue, essentially creating a large 'hole' in the Swiss Cheese Model's technology slice. The proposal to raise the severity threshold has legitimate benefits: it would reduce noise, increase the signal-to-noise ratio of remaining alerts, and potentially improve pharmacist engagement with the alerts that do fire. However, the risk is that clinically significant but lower-severity interactions may be missed entirely. From a just culture perspective, the high override rate should not be treated as pharmacist noncompliance (reckless behavior) but rather as a system design failure (the alerts are poorly tiered and include too many clinically insignificant notifications), warranting system redesign rather than individual discipline. Complementary approaches include: (1) implementing a tiered alert system with hard stops reserved for the most dangerous interactions (e.g., contraindicated combinations) and interruptive alerts for moderate-severity interactions, while routing minor interactions to a non-interruptive information panel; (2) conducting a retrospective analysis of overridden alerts to identify which categories are consistently overridden and whether any overrides were associated with subsequent patient harm; (3) involving frontline pharmacists in redesigning alert parameters (deference to expertise, an HRO principle); and (4) establishing a feedback loop so that pharmacists see outcomes data on their override decisions, reinforcing the value of appropriate alert responses.

SUMMARY

Lesson Summary

Summary

Risk management in pharmacy is a systems-oriented discipline rooted in the landmark To Err Is Human report and built upon foundational models including the Swiss Cheese Model of layered defenses, Just Culture for proportional accountability, and High-Reliability Organization (HRO) principles for proactive hazard vigilance. Medication errors are classified using the NCC MERP Index (Categories A through I) and are analyzed retrospectively through Root Cause Analysis (RCA) or prospectively through Failure Mode and Effects Analysis (FMEA), which quantifies risk using the formula RPN = Severity × Occurrence × Detectability.

Prevention strategies are most effective when they follow the hierarchy of controls, prioritizing forcing functions and technology-based automation (CPOE, BCMA, smart pumps, tall-man lettering, ADCs) over education-only approaches. Key metrics such as medication error rates enable continuous monitoring, and advanced paradigms like Safety-II and Resilience Engineering extend the field by studying successful performance adaptations. For the NAPLEX, master ISMP high-alert medication lists, the five rights, NCC MERP categories, RCA versus FMEA distinctions, REMS programs, and the effectiveness hierarchy of error prevention strategies.

Varsity Tutors • NAPLEX • Risk Management And Error Prevention